These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38353949)

  • 1. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
    Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
    JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China.
    Sun L; Cui B; Wei X; Sadique Z; Yang L; Manchanda R; Legood R
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
    Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
    Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
    Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation of Population-Based
    Manchanda R; Sun L; Patel S; Evans O; Wilschut J; De Freitas Lopes AC; Gaba F; Brentnall A; Duffy S; Cui B; Coelho De Soarez P; Husain Z; Hopper J; Sadique Z; Mukhopadhyay A; Yang L; Berkhof J; Legood R
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    Hurry M; Eccleston A; Dyer M; Hoskins P
    Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
    Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.